Houston biomanufacturing accelerator adds pilot plant to support scale-ups

new digs

BioWell will now operate Texas BioTechnology’s 33,000-square-foot pilot plant. Photo courtesy First Bight Ventures.

Houston accelerator BioWell announced this month that it has taken over operations of Texas BioTechnology’s pilot plant in Richmond, Texas.

The 33,000-square-foot facility is one of the largest of its kind in the U.S. and features molecular biology labs, advanced automation, fermentation equipment and 16 dedicated benches for early-stage industrial biomanufacturing companies, according to a release from the company. It will allow BioWell to offer on-site education, workforce development, and lab training for students and workers.

BioWell and its founding company, First Bight Ventures, report that the facility should help address the industry's "scale-up bottleneck due to limited pilot- and demonstration-scale infrastructure" in the U.S.

"As a Houston-based accelerator dedicated exclusively to early-stage biomanufacturing startups, partnering with this facility was a natural and highly strategic decision for us. The site is fully operational and offers a strong platform to support biomanufacturing companies, industry leaders, and research institutions, providing critical expertise and infrastructure across a broad range of biotechnology production processes,” Veronica Breckenridge, founder of First Bight Ventures and BioWell, said in a news release.

First Bight Ventures shares that the partnership with the facility will also allow it to better support its portfolio companies and make them more attractive to future investors.

BioWell will host an open house and tours of the fermentation and lab spaces and an overview of current bioindustrial projects Wednesday, May 28, at 10:30 a.m. and 2 p.m. RSVPs are required.

BioWell was originally funded by a $700,000 U.S. Economic Development Administration’s Build to Scale grant and launched as a virtual accelerator for bioindustrial startups. Listen to an interview with Carlos Estrada, head of venture acceleration at BioWell, here.

From Your Site Articles
Clockwise from top left: Jesse Martinez, Adrianne Stone, Phillip Yates, Carlos Estrada, Atul Varadhachary, and Juliana Garaizar. Photos courtesy

Top innovation leaders talk Houston's strengths, weaknesses

finalists weigh in

The six finalists in this year's Ecosystem Builder category for the Houston Innovation Awards shared many reasons why Houston has been a great place for them to launch their startups.

Still, they've seen first-hand how Houston can grow and change to better support founders like themselves. We asked each to share their thoughts on the strengths and weaknesses of the local innovation ecosystem and about the roles they're playing in the scene's evolution. Scroll down to see what each finalist had to say.

Secure your tickets to the November 14 event.


What are the strengths of the Houston innovation ecosystem?

Adrianne Stone, founder of Bayou City Startups: "Outside of our obvious advantages in health care, energy and space technology I would say that our biggest strength is in the diversity of our community. Everyone brings such unique perspectives, experiences, and ideas to the table that it allows Houston to truly think outside of the box when we leverage that superpower."

Atul Varadhachary, managing partner at Fannin Innovation Studio: "The city benefits from its strategic location as a hub for various industries, including energy, aerospace and health care/biotechnology. This diversity of sectors fosters cross-pollination of ideas and expertise, promoting innovation in multiple fields. In the biotechnology field, the Texas Medical Center in Houston, is a major driver of intellectual capital and contributes to a highly skilled workforce. This potential has not been fully leveraged as yet, but I have seen and contributed to much progress over the last three decades."

Carlos Estrada, growth partner at First Bight Ventures and head of venture acceleration at BioWell: "Houston’s strengths lie in its diverse industries, from energy to health care to bioindustrial manufacturing and its academic institutions which nurture talent and innovation. A new wave of startup organizations also provides startups and SMBs with mentorship, funding opportunities, and critical networking connections. This combination of industry diversity, academic excellence and supportive organizations creates an ideal environment for startups to grow."

Jesse Martinez, founder and CEO of invincible: "The Houston innovation ecosystem continues evolving as it naturally pivots and iterates like a startup. We have a number of existing and new stakeholders who deeply care about Houston, as we all work together to make it a global tech hub destination. Through our SDOs, TMC, Houston Methodist, Helix Park, The Ion, NASA, our universities, and startup community leaders, it's all about us helping to connect the dots for our entrepreneurs so they may grow and thrive in Houston."

Juliana Garaizar, founding partner of Energy Tech Nexus: "Houston has the talent, the corporations and the great intersection of industries were innovations happen: energy, medical and space. Houston knows how to do hard things. We are doers, and we know how to build on our key strengths and are resilient when things don't go according to plan. Our geographic situation and our port make us a global hub and the most diverse city in the U.S."

Phillip Yates, CEO of Equiliberty Inc.: "I believe Houston's innovative ecosystem's greatest strengths reside in its diverse group of citizens and our healthy local economy, which includes the energy sector, medical, and aerospace industries."

What are the weaknesses of the Houston innovation ecosystem? Are you helping to make improvements to these weaker aspects of the community and, if so, how?

Stone: "The first thing that comes to mind is a lack of early stage funding for startups, especially for those with founders from underserved backgrounds. And the second thing is the sheer size of our geographic distribution makes it hard for folks to connect and those kismet collisions to occur. I'm working to improve this by inviting investors to our events, networking more broadly outside of the region and inviting folks to come back to visit, and by hosting a predictable recurring meetup every month so folks can get plugged into the broader ecosystem."

Varadhachary: "In the life sciences space, where I primarily play, our biggest challenge is that the early-stage drug development process is complex and requires direct product development experience. At Fannin, I have helped address this challenge by creating one of the largest talent development programs in the U.S., boasting over 350 alumni. I am especially proud of our alumni diversity — about half are women and most are BIPOC. Fannin draws from local institutions and major institutions across the country. Half of our alumni remain in Houston, many of whom, alongside students I’ve taught, have gone on to join or found startups. Other Fannin alumni have joined major companies around the U.S. and have often come back to help support our local ecosystem."

Estrada: "Houston’s biggest challenge is limited early-stage venture capital. To address this, I organized pitch events at WeWork Labs to attract outside investors and guided startups on how to raise funds while keeping their headquarters in Houston. Furthermore at Rice University’s Liu Idea Lab and Rice Alliance, supporting commercialization was key to launching more local scientist-entrepreneur-led startups. Through First Bight Ventures, I also support local startups like Via Fuels and attract outside startups to scale their manufacturing operations in Houston, further growing the ecosystem."

Martinez: "The current weaknesses of our current Houston innovation ecosystem is two-fold: We need true early stage capital (pre-seed and seed) to support our founders. We also need more incubators and accelerators across the Houston area to support our geographically disbursed founders and founders-to-be in The Woodlands, Katy, and Sugar Land, along with more in central Houston. At invincible, we are committed to helping support and champion our Houston-area innovation community by launching a Mom Tech Incubator (HERA), an early-stage fund, and an industry-specific venture studio. Long term, we will need a growth-stage fund to better support our local startups and those expanding here for strategic reasons."

Garaizar: "Although Houston has a lot of later stage capital, access to early stage capital is a weakness that we are trying to overcome with capital activation, formation and innovation finance. Although Houston is the most diverse city in the U.S. it is not the most inclusive and equitable, that is why I studied the gender gap in investing and launched initiatives like Portfolia or the Houston Equitable Energy Transition Initiative and I am part of the City of Houston's Women Commission."

Yates: "Houston has a problem with economic disparities, including income inequality, poverty, and lack of access to resources. These economic indicators create real barriers for some individuals to have meaningful access to the Houston innovative ecosystem.Through my work with Equiliberty and other non-profits, I have provided my time and resources to help build a more equitable ecosystem. Through the work I am doing with Equiliberty, Houston Area Urban League, Impact Hub and others, I believe we're making improvements to ensure that any person with a dream of changing the world can do it right here in Houston, Texas. We are all working towards the day when their ZIP code, education background or financial status will not be a determining factor."

This week's roundup of Houston innovators includes Carlos Estrada of BioWell, Elizabeth Gore of Hello Alice, and Daniel Barvin of Coya Therapeutics. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a podcast with the leader of a new bioindustrial accelerator, a fintech leader celebrating a big win, and an operations expert fighting for an ALS cure.

Carlos Estrada, head of Venture Acceleration at BioWell

Carlos Estrada, head of Venture Acceleration at BioWell, joins the Houston Innovators Podcast to share why Houston is already a great hub for bioindustrial innovation. Photo courtesy of BioWell

Bioindustrial technologies have a high potential for impacting sustainability — but they tend to need a little bit more help navigating the startup valley of death. That's where the BioWell comes in.

Carlos Estrada, head of Venture Acceleration at BioWell, says the idea for the accelerator was came to First Bight Ventures, a Houston-based biomanufacturing investment firm, as it began building its portfolio of promising companies.

"While we were looking at various companies, we found ourselves finding different needs that these startups have," Estrada says on the Houston Innovators Podcast. "That's how the opportunity for the BioWell came about." Read more.

Elizabeth Gore, co-founder and president of Hello Alice

It's a win for Hello Alice and Elizabeth Gore, co-founder and president (right). Photo courtesy Cayce Clifford/Hello Alice

A Houston fintech company is celebrating the dismissal of a lawsuit from former Trump Administration officials.

Last year, America First Legal sued Houston-based Hello Alice and its partner, Progressive Insurance, alleging that their program to award 10 $25,000 grants to Black-owned small businesses constitutes racial discrimination. AFL was founded by former Trump Administration adviser Stephen Miller and features a handful of other former White House officials on its board.

The case has been dismissed by a federal judge in Ohio, who said that the “Plaintiffs fail to allege any injury in fact that would support their standing to seek either retrospective or prospective relief," according to a news release from Hello Alice.

“This resolution marks a pivotal moment not only for our company but for the broader small business community in the United States,” Elizabeth Gore, co-founder and president of Hello Alice, says in the release. “Facing a labor shortage, heightened interest rates, and inflation, this country needs its small business owners, and they, in return, need the capital and resources that programs like Hello Alice provide." Read more.

Daniel Barvin, vice president of operations and patient advocacy at Coya Therapeutics

Daniel Barvin has a neurodegenerative disease in his near future. He joined Houston-based Coya Therapeutics to help fight for a cure to the aggressively deadly ALS. Photo courtesy

When genetic testing proved to Daniel Barvin that he, like his grandfather, aunt, uncle, and father before him, would most likely die of amyotrophic lateral sclerosis, more commonly known as ALS, and/or frontotemporal degeneration (FTD) in his 40s, he didn't slow him down.

in a guest column for InnovationMap, he writes "instead I chose to fight for every chance to change not only my life, but the lives of millions who are suffering or may one day suffer from neurodegenerative disease."

He joined Houston-based Coya Therapeutics in 2021 to support operations and patient advocacy at a company actively developing a therapeutic that can fight neurodegenerative diseases like ALS. Read more.

Carlos Estrada, head of Venture Acceleration at BioWell, joins the Houston Innovators Podcast to share why Houston is already a great hub for bioindustrial innovation. Photo courtesy of BioWell

Houston innovator drives new accelerator toward supporting promising bioindustrial startups

HOUSTON INNOVATORS PODCAST EPISODE 238

Bioindustrial technologies have a high potential for impacting sustainability — but they tend to need a little bit more help navigating the startup valley of death. That's where the BioWell comes in.

Carlos Estrada, head of Venture Acceleration at BioWell, says the idea for the accelerator was came to First Bight Ventures, a Houston-based biomanufacturing investment firm, as it began building its portfolio of promising companies.

"While we were looking at various companies, we found ourselves finding different needs that these startups have," Estrada says on the Houston Innovators Podcast. "That's how the opportunity for the BioWell came about."

Specifically, bioindustrial companies, which are tapping into life science innovation to create more sustainable products or services, need early funding, lab space, and strategic corporate partners to help research and develop their startups.

"The very direct challenge that we are seeing is that these companies very often have to spend their funds to build out their own lab spaces," Estrada says, "so by the time they're trying to focus back on the product itself, they are starting to run out of funding."

BioWell is currently selecting its inaugural cohort and is also actively searching for its physical location to build out the program and facilities. Last year, BioWell secured $741,925 of the $53 million doled out as a part of the "Build to Scale" Grant program from the U.S. Economic Development Administration.

In addition to solving for specific challenges bioindustrial companies face, Estrada says the program will provide support for general startup and entrepreneurial guidance, like business plan development, navigating investors and grant funding, and more.

Just as First Bight Ventures was founded strategically in Houston to make the most of the local resources, the BioWell will operate out of the Bayou City — a market Estrada says has everything the industry needs.

"We have the right talent — our universities produce great researchers. We have the energy companies that are utilizing (a workforce) with transferable skills," he says on the show. "We also have the infrastructure, the square footage, and various real estate companies creating shells for lab space. We have the know how, the universities, and all at a lower cost, which plays a big role in the equation."

This week's roundup of Houston innovators includes Mitra Miller of Houston Angel Network, Richard Baraniuk of OpenStax, and Carlos Estrada of BioWell. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to three Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a podcast with an angel investment evangelist, an academic-turned-startup-founder celebrating a big win, and a leader of a brand new accelerator.

Mitra Miller, vice president and board member of the Houston Angel Network

Mitra Miller, vice president and board member of the Houston Angel Network, joins the Houston Innovators Podcast to share her passion for growing angel investors in Houston. Photo via LinkedIn

One of the biggest components of a well-functioning startup ecosystem is inarguably access to capital, and Mitra Miller is dedicated to enhancing education around investment and growing Houston's investor base.

As vice president and board member of the Houston Angel Network, the oldest angel network in Texas and one of the most active angel networks in the country, Miller strives to provide guidance to new and emerging angel investors as well as founders seeking to raise money from them.

"Most founders have no idea or understanding of how investors think — we are not an ATM," Miller says on the Houston Innovators Podcast. "We are really partners you are getting married to for the next 5, 8, 10 years — sometimes longer. We need to bring your allies in every sense of the word." Continue reading.

Richard Baraniuk, Rice University professor and founder of OpenStax

At an event at the Ion, OpenStax and Rice University announced a $90 million NSF-backed initiative. Photo by Jeff Fitlow/Rice

An educational technology company based out of Rice University has received $90 million to create and lead a research and development hub for inclusive learning and education research. It's the largest research award in the history of the university.

OpenStax received the grant funding from the U.S. National Science Foundation for a five-year project create the R&D hub called SafeInsights. Richard Baraniuk, who founded OpenStax and is a Rice professor, will lead SafeInsights. He says he hopes the initiative will allow progress to be made for students learning in various contexts.

“Learning is complex," Baraniuk says in the release. "Research can tackle this complexity and help get the right tools into the hands of educators and students, but to do so, we need reliable information on how students learn. Just as progress in health care research sparked stunning advances in personalized medicine, we need similar precision in education to support all students, particularly those from underrepresented and low-income backgrounds.” Continue reading.

Carlos Estrada, head of venture acceleration at BioWell

Calling all biotechnology startups. Photo via LinkedIn

A Houston organization — freshly funded by a $700,000 U.S. Economic Development Administration’s “Build to Scale” grant — is seeking its first accelerator cohort of industrial biology startups.

Founded by Houston-based First Bight Ventures, the BioWell has launched a virtual accelerator program that will provide programming, networking, mentorship, and financial resources to its inaugural cohort of 10 bioindustrial startups. The selected companies will also have access to specialized pilot bioproduction infrastructure throughout the nine-month program.

“BioWell equips startups with more than just capital. We provide a foundation for breakthrough innovations by combining access to cutting-edge bioproduction facilities with expertise that nurtures scalability. This comprehensive support is crucial for transforming pioneering ideas into market-ready solutions that can address pressing global challenges,” Carlos Estrada, head of venture acceleration at BioWell, says in a news release. Continue reading.

Calling all biotechnology startups. Photo via Getty Images

Houston organization launches virtual accelerator, seeks 10 biotech startups

calling for applicants

A Houston organization — freshly funded by a $700,000 U.S. Economic Development Administration’s “Build to Scale” grant — is seeking its first accelerator cohort of industrial biology startups.

Founded by Houston-based First Bight Ventures, the BioWell has launched a virtual accelerator program that will provide programming, networking, mentorship, and financial resources to its inaugural cohort of 10 bioindustrial startups. The selected companies will also have access to specialized pilot bioproduction infrastructure throughout the nine-month program.

“BioWell equips startups with more than just capital. We provide a foundation for breakthrough innovations by combining access to cutting-edge bioproduction facilities with expertise that nurtures scalability. This comprehensive support is crucial for transforming pioneering ideas into market-ready solutions that can address pressing global challenges,” Carlos Estrada, head of venture acceleration at BioWell, says in a news release.

Applications for the program are open until May 15, and the cohort will be announced in June. Specifically, BioWell is seeking seed or pre-seed startup applicants that have a technology readiness level of 3 to 5, focusing on areas including low-cost and sustainable feedstocks, commercially viable yields, and purpose fit microbes.

“During our selection process, we'll prioritize startups that demonstrate a commitment to not only hitting milestones but also to building sustainable revenue streams for long-term survival. This phase necessitates keen awareness of market dynamics, customer demands, and sound financial management,” adds First Bight Ventures and BioWell Founder Veronica Wu.

In December, BioWell secured $741,925 of the $53 million doled out as a part of the "Build to Scale" Grant program that the U.S. Economic Development Administration, a division of the U.S. Department of Commerce, has established. First Bight was one of 60 organizations to receive funding.

Ex-Apple exec Wu founded First Bight Ventures in Houston in 2022 after relocating from Silicon Valley and seeing the region's potential for biotech.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings